Cargando…
Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1–JNK–DRP1 pathway
BACKGROUND: Acute liver failure (ALF) is associated with a high mortality rate, and there are still no effective treatments except liver transplantation and artificial liver therapies. This study aimed to determine the effects, therapeutic window and mechanisms of selonsertib, a selective inhibitor...
Autores principales: | Lou, Guohua, Li, Aichun, Cen, Yelei, Yang, Qin, Zhang, Tianbo, Qi, Jinjin, Chen, Zhi, Liu, Yanning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792153/ https://www.ncbi.nlm.nih.gov/pubmed/33413667 http://dx.doi.org/10.1186/s13578-020-00525-w |
Ejemplares similares
-
Adipose-Derived Mesenchymal Stem Cells Inhibit JNK-Mediated Mitochondrial Retrograde Pathway to Alleviate Acetaminophen-Induced Liver Injury
por: Cen, Yelei, et al.
Publicado: (2023) -
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
por: Loomba, Rohit, et al.
Publicado: (2017) -
Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/MAPK Pathway of Hepatic Stellate Cells
por: Yoon, Young-Chan, et al.
Publicado: (2020) -
A new perspective on mesenchymal stem cell-based therapy for liver diseases: restoring mitochondrial function
por: Cen, Yelei, et al.
Publicado: (2023) -
Selonsertib Alleviates the Progression of Rat Osteoarthritis: An in vitro and in vivo Study
por: Yan, Jiyuan, et al.
Publicado: (2021)